|
|
利奈唑胺致新生儿血小板减少1例并文献复习
|
Abstract:
利奈唑胺通常用于治疗新生儿多重耐药革兰氏阳性菌感染。新生儿属特殊用药群体，其器官功能尚未发育成熟，利奈唑胺的药品不良反应发生率，尤其是利奈唑胺所致血小板减少的风险值得重视。新生儿使用利奈唑胺后的不良反应主要表现为血小板减少、血红蛋白降低及粒细胞减少等血液系统毒性反应，停药后可恢复正常。本文介绍1例重症感染后应用利奈唑胺致重度血小板减少患者的临床资料，以提高临床医师对利奈唑胺致新生儿不良反应规范化诊疗的认知。
Linezolid is commonly used for the treatment of multi-drug resistant Gram-positive bacterial infections in neonates. Neonates are a special group of drug users whose organ functions are not yet mature, and the incidence of adverse drug reactions to linezolid, especially the risk of thrombocytopenia caused by linezolid, is worthy of attention. Adverse reactions in neonates after using linezolid are mainly manifested as thrombocytopenia, hemoglobin reduction granulocytopenia and other hematologic toxic reactions, which can be restored to normal after stopping the drug. In this article, we present the clinical data of a patient with severe thrombocytopenia caused by the application of linezolid after severe infection to improve the clinicians’ knowledge of standardized diagnosis and treatment of linezolid-induced adverse reactions in neonates.
| [1] | Chiappini, E., Conti, C., Galli, L. and de Martino, M. (2010) Clinical Efficacy and Tolerability of Linezolid in Pediatric Patients: A Systematic Review. Clinical Therapeutics, 32, 66-88. https://doi.org/10.1016/j.clinthera.2010.01.019 |
| [2] | 崔向丽, 赵志刚. 新型噁唑烷酮类抗生素利奈唑胺[J]. 中国新药杂志, 2008(6): 530-533. |
| [3] | 自雪梅, 张峻, 何瑾. 利奈唑胺血药浓度监测研究进展[J]. 中国现代应用药学, 2022, 39(3): 424-428. |
| [4] | Gostelow, M., Gonzalez, D., Smith, P.B. and Cohen-Wolkowiez, M. (2014) Pharmacokinetics and Safety of Recently Approved Drugs Used to Treat Methicillin-Resistant Staphylococcus aureus Infections in Infants, Children and Adults. Expert Review of Clinical Pharmacology, 7, 327-340. https://doi.org/10.1586/17512433.2014.909281 |
| [5] | Sotgiu, G., Centis, R., D'Ambrosio, L., Alffenaar, J.C., Anger, H.A., Caminero, J.A., et al. (2012) Efficacy, Safety and Tolerability of Linezolid Containing Regimens in Treating MDR-TB and XDR-TB: Systematic Review and Meta-analysis. European Respiratory Journal, 40, 1430-1442. https://doi.org/10.1183/09031936.00022912 |
| [6] | Cattaneo, D., Orlando, G., Cozzi, V., Cordier, L., Baldelli, S., Merli, S., et al. (2013) Linezolid Plasma Concentrations and Occurrence of Drug-Related Haematological Toxicity in Patients with Gram-Positive Infections. International Journal of Antimicrobial Agents, 41, 586-589. https://doi.org/10.1016/j.ijantimicag.2013.02.020 |
| [7] | Hanai, Y., Matsuo, K., Ogawa, M., Higashi, A., Kimura, I., Hirayama, S., et al. (2016) A Retrospective Study of the Risk Factors for Linezolid-Induced Thrombocytopenia and Anemia. Journal of Infection and Chemotherapy, 22, 536-542. https://doi.org/10.1016/j.jiac.2016.05.003 |
| [8] | Boak, L.M., Rayner, C.R., Grayson, M.L., Paterson, D.L., Spelman, D., Khumra, S., et al. (2014) Clinical Population Pharmacokinetics and Toxicodynamics of Linezolid. Antimicrobial Agents and Chemotherapy, 58, 2334-2343. https://doi.org/10.1128/aac.01885-13 |
| [9] | Shane, A.L., Sánchez, P.J. and Stoll, B.J. (2017) Neonatal Sepsis. The Lancet, 390, 1770-1780. https://doi.org/10.1016/s0140-6736(17)31002-4 |
| [10] | Greer, O., Shah, N.M., Sriskandan, S. and Johnson, M.R. (2019) Sepsis: Precision-Based Medicine for Pregnancy and the Puerperium. International Journal of Molecular Sciences, 20, Article No. 5388. https://doi.org/10.3390/ijms20215388 |
| [11] | Zaidi, A.K.M., Ganatra, H.A., Syed, S., Cousens, S., Lee, A.C., Black, R., et al. (2011) Effect of Case Management on Neonatal Mortality Due to Sepsis and Pneumonia. BMC Public Health, 11, S13. https://doi.org/10.1186/1471-2458-11-s3-s13 |
| [12] | Weston, E.J., Pondo, T., Lewis, M.M., Martell-Cleary, P., Morin, C., Jewell, B., et al. (2011) The Burden of Invasive Early-Onset Neonatal Sepsis in the United States, 2005-2008. Pediatric Infectious Disease Journal, 30, 937-941. https://doi.org/10.1097/inf.0b013e318223bad2 |
| [13] | Osrin, D., Vergnano, S. and Costello, A. (2004) Serious Bacterial Infections in Newborn Infants in Developing Countries. Current Opinion in Infectious Diseases, 17, 217-224. https://doi.org/10.1097/00001432-200406000-00008 |
| [14] | Oza, S., Lawn, J.E., Hogan, D.R., Mathers, C. and Cousens, S.N. (2014) Neonatal Cause-of-Death Estimates for the Early and Late Neonatal Periods for 194 Countries: 2000-2013. Bulletin of the World Health Organization, 93, 19-28. https://doi.org/10.2471/blt.14.139790 |
| [15] | Hayes, R., Hartnett, J., Semova, G., Murray, C., Murphy, K., Carroll, L., et al. (2021) Neonatal Sepsis Definitions from Randomised Clinical Trials. Pediatric Research, 93, 1141-1148. https://doi.org/10.1038/s41390-021-01749-3 |
| [16] | Greenberg, R.G., Kandefer, S., Do, B.T., Smith, P.B., Stoll, B.J., Bell, E.F., et al. (2017) Late-Onset Sepsis in Extremely Premature Infants. Pediatric Infectious Disease Journal, 36, 774-779. https://doi.org/10.1097/inf.0000000000001570 |
| [17] | Pokhrel, B., Koirala, T., Shah, G., Joshi, S. and Baral, P. (2018) Bacteriological Profile and Antibiotic Susceptibility of Neonatal Sepsis in Neonatal Intensive Care Unit of a Tertiary Hospital in Nepal. BMC Pediatrics, 18, Article No. 208. https://doi.org/10.1186/s12887-018-1176-x |
| [18] | Tsai, M., Hsu, J., Chu, S., Lien, R., Huang, H., Chiang, M., et al. (2014) Incidence, Clinical Characteristics and Risk Factors for Adverse Outcome in Neonates with Late-Onset Sepsis. Pediatric Infectious Disease Journal, 33, e7-e13. https://doi.org/10.1097/inf.0b013e3182a72ee0 |
| [19] | 中华医学会儿科学分会新生儿学组, 中华儿科杂志编辑委员会. 新生儿败血症诊断与治疗专家共识(2024) [J]. 中华儿科杂志, 2024(10): 931-940. |
| [20] | Özkavaklı, A., Yalın İmamoğlu, E., Önder, N., İmamoğlu, S. and Ovalı, H.F. (2024) Trends in Causative Organisms and Antimicrobial Resistance in Late-Onset Neonatal Sepsis. Turkish Archives of Pediatrics, 59, 375-382. https://doi.org/10.5152/turkarchpediatr.2024.24006 |
| [21] | 尹向辉, 薛兴翠. 利奈唑胺治疗重症肺炎的临床疗效及安全性研究[J]. 中国地方病防治, 2017, 32(10): 1192. |
| [22] | Thibault, C., Kassir, N., Goyer, I., Théorêt, Y., Litalien, C., Moussa, A., et al. (2019) Population Pharmacokinetics of Intravenous Linezolid in Premature Infants. Pediatric Infectious Disease Journal, 38, 82-88. https://doi.org/10.1097/inf.0000000000002067 |
| [23] | Giunio-Zorkin, N. and Brown, G. (2019) Real-Life Frequency of New-Onset Thrombocytopenia during Linezolid Treatment. The Canadian Journal of Hospital Pharmacy, 72, 133-138. https://doi.org/10.4212/cjhp.v72i2.2883 |
| [24] | Crass, R.L., Cojutti, P.G., Pai, M.P. and Pea, F. (2019) Reappraisal of Linezolid Dosing in Renal Impairment to Improve Safety. Antimicrobial Agents and Chemotherapy, 63, e00605-00619. https://doi.org/10.1128/aac.00605-19 |
| [25] | 唐莲, 王三南, 翁小红, 等. 利奈唑胺治疗新生儿败血症的疗效及对血小板的影响[J]. 药物不良反应杂志, 2016, 18(2): 99-104. |
| [26] | Duan, L., Zhou, Q., Feng, Z., Zhu, C., Cai, Y., Wang, S., et al. (2022) A Regression Model to Predict Linezolid Induced Thrombocytopenia in Neonatal Sepsis Patients: A Ten-Year Retrospective Cohort Study. Frontiers in Pharmacology, 13, Article ID: 710099. https://doi.org/10.3389/fphar.2022.710099 |
| [27] | Chen, C., Guo, D., Cao, X., Cai, Y., Xu, Y., Zhu, M., et al. (2012) Risk Factors for Thrombocytopenia in Adult Chinese Patients Receiving Linezolid Therapy. Current Therapeutic Research, 73, 195-206. https://doi.org/10.1016/j.curtheres.2012.07.002 |
| [28] | Bernstein, W.B., Trotta, R.F., Rector, J.T., Tjaden, J.A. and Barile, A.J. (2003) Mechanisms for Linezolid-Induced Anemia and Thrombocytopenia. Annals of Pharmacotherapy, 37, 517-520. https://doi.org/10.1345/aph.1c361 |
| [29] | Abena, P.A. (2001) Linezolid and Reversible Myelosuppression. JAMA: The Journal of the American Medical Association, 286, 1973-1974. https://doi.org/10.1001/jama.286.16.1973 |
| [30] | Fromenty, B. (2020) Alteration of Mitochondrial DNA Homeostasis in Drug-Induced Liver Injury. Food and Chemical Toxicology, 135, Article ID: 110916. https://doi.org/10.1016/j.fct.2019.110916 |
| [31] | 李思婵, 徐华, 叶琦, 等. 利奈唑胺在儿童体内暴露量与血小板减少症发生风险的关系研究[J]. 中华医院感染学杂志, 2019, 29(21): 3311-3315. |
| [32] | Oda, K., Tsuruta, T., Hanai, Y., Yamada, T., Komatsu, T., Kondo, S., et al. (2025) Personalized Dosing of Linezolid to Reduce the Risk of Thrombocytopenia: A Systematic Review and Meta-Analysis. Therapeutic Drug Monitoring. https://doi.org/10.1097/ftd.0000000000001300 |
| [33] | Inoue, Y., Kashiwagi, H., Sato, Y., Nashimoto, S., Sugawara, M. and Takekuma, Y. (2024) Exploring the Impact of Baseline Platelet Count on Linezolid-Induced Thrombocytopenia: A Retrospective Single-Center Observation Study. International Journal of Clinical Pharmacy, 47, 90-98. https://doi.org/10.1007/s11096-024-01810-1 |
| [34] | Huo, B., Wu, Y., Shu, L., Zhang, R., Xiao, J., Li, Q., et al. (2022) Relationship between Linezolid Exposure and the Typical Clinical Laboratory Safety and Bacterial Clearance in Chinese Pediatric Patients. Frontiers in Pharmacology, 13, Article ID: 926711. https://doi.org/10.3389/fphar.2022.926711 |
| [35] | 曲俊兵. 利奈唑胺的研究进展[J]. 中国药业, 2010, 19(1): 60-61. |
| [36] | 黎颖然, 卢荣枝. 利奈唑胺相关新生儿血小板减少4例[J]. 药物不良反应杂志, 2011, 13(4): 243-244. |
| [37] | Kato, H., Hagihara, M., Asai, N., Koizumi, Y., Yamagishi, Y. and Mikamo, H. (2021) A Systematic Review and Meta-Analysis of Myelosuppression in Pediatric Patients Treated with Linezolid for Gram-Positive Bacterial Infections. Journal of Infection and Chemotherapy, 27, 1143-1150. https://doi.org/10.1016/j.jiac.2021.03.003 |
| [38] | Jungbluth, G.L., Welshman, I.R. and Hopkins, N.K. (2003) Linezolid Pharmacokinetics in Pediatric Patients: An Overview. Pediatric Infectious Disease Journal, 22, S153-S157. https://doi.org/10.1097/01.inf.0000086954.43010.63 |
| [39] | 张丽. 万古霉素与利奈唑胺治疗新生儿革兰阳性菌败血症临床疗效及对胆红素和血小板的影响比较[J]. 儿科药学杂志, 2018, 24(11): 7-10. |
| [40] | 王斌霞, 段露芬, 陆件, 等. 利奈唑胺诱导血小板减少症的危险因素及其预警价值分析[J]. 药物不良反应杂志, 2022(4): 185-191. |
| [41] | 赵宏明, 唐莲, 虞燕霞, 等. 利奈唑胺致新生儿与老年患者血小板减少分析[J]. 中国医院药学杂志, 2013, 33(10): 803-806. |
| [42] | Yang, S., Guo, W., Chen, M., Hu, J., Feng, N., Ju, M., et al. (2023) Prevalence and Risk Factors for Severe Linezolid-Associated Thrombocytopenia in Pediatric Patients: An Analysis of a Public Database. Medicine, 102, e34059. https://doi.org/10.1097/md.0000000000034059 |
